Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

Cancer

Volumn 68, Issue 2, 1991, Pages 227-232

  Moertel, Charles G ^a   Kvols, Larry K ^a   O'Connell, Michael J ^a   Rubin, Joseph ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ANEMIA; ARTICLE; CARCINOID; CLINICAL ARTICLE; FEMALE; HUMAN; LEUKOPENIA; MALE; NEUROENDOCRINE TUMOR; NEUROPATHY; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADENOMA, ISLET CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; CARCINOMA; CISPLATIN; ETOPOSIDE; FEMALE; GASTRINS; GLUCAGON; HUMAN; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGE; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE;

EID: 0025933213     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I     Document Type: Article

References (5)

1. Treatment of metastatic carcinoid and Merkel cell tumors with cisplatin and etoposide (Abstr)
2. A phase I‐II study of sequential infusion VP‐16 and cisplatin therapy in advanced lung cancer
3. Carcinoids: The association of histologic growth pattern and survival
4. Neuroendocrine carcinomas of the colon and rectum: A clinicopathologic evaluation
5. Poorly differentiated neuroendocrine carcinoma of unknown primary site